DAFTAR PUSTAKA

1. McMahon BJ. Natural history of chronic hepatitis B. Clin Liver Dis. 2010 August;
14(3): 381─96.

2. Lesmana RA, Lesmana LA. Hepatitits B di Indonesia dari molekuler sampai ke terapi
Jakarta; 2015:1─100.

3. Terrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM, Murad MH. AASLD
Guidelines for treatment of chronic hepatitis B. HEPATOLOGY. 2016 January; 63(1):
261─83.

4. Tram T, Tran. Hepatitis B in pregnancy. CID. 2016; 62(4): 314─7.

5. Gani RA, Hasan I, Djumhana A, Setiawan PB. Konsensus nasional penatalaksanaan

hepatitis B di Indonesia 2012. editor:Akbar N. PPHI; 2012:1─45.

6. Liaw YF, Gane E, Leung N, Zeuzem S, Wang Y, Lai CL. Asian-Pasific consensus
statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int. 2012;
6(3): 531─61.

7. Isogawa M, Tanaka Y. Immunobiology of hepatitis B virus infection. Hepatology

Research. 2015; 45: 179─89.

8. Boesecke C, Wasmuth JC. Hepatitis B. In Stefan M, Berg T, Rockstroh J, Sarrazin C,

editors. In Hepatology 2012. 3rd ed.: Cologne: Flying Publisher; 2012: 32─43.

9. Lesmana CR, Hasan I, Gani RA, Sanityoso A, Setiawan PB, Djumhana A. Konsensus
nasional penatalaksanaan hepatitis B di Indonesia 2017. editor: Lesmana CR. PPHI;
Jakarta; 2017: 1─82.

10. Wibawa I, Primadharsini PP. Imunobiologi dan imunoterapi hepatitis B kronis.

Div.Gastroentero-hepatologi, Dept.Ilmu Penyakit Dalam FK Unud/RSUP Sanglah
Denpasar; 2017: 1─9.

11. Kondo Y, Kobayashi K, Asabe S, Shiina M, Niitsuma H, Ueno Y, et al. Vigorous

response of cytotoxic T lymphocytes associated with systemic activation of CD8 T
lymphocytes in fulminant hepatitis B. Liver Int. 2004; 24: 561─7.

12. Yang P, Althage A, Chung J, Maier H, Wieland S, Isogawa M, et al. Immune effectors
 required for hepatitis B virus clearance. Proc Natl Acad Sci USA. 2010; 107: 798─802.

13. Boni C, Penna A, Ogg G. Lamivudine treatment can overcome cytotoxic T-cell
hyporesponsiveness in chronic hepatitis B: new perspectives for immune therapy.
Hepatology. 2001; 33: 963─71.

14. Purnomo HD. Respon imun pada infeksi virus hepatitis B kronik. In Surabaya Weekend
Course; Surabaya; 2016: 1─9.

15. Shimizu Y. T cell immunopathogenesis and immunotherapeutic strategies for chronic

hepatitis B virus infection. World J Gastroenterol. 2012; 18: 2443─51.

16. Fife BT, Pauken KE. The role of the PD-1 pathway in autoimmunity and peripheral
tolerance. Ann N Y Acad Sci. 2011; 1217: 45─59.

17. Chen J, Wang XM, Wu XJ, Wang Y, Zhao H, Shen B, et al. Intrahepatic levels of PD-
1/PD-L correlate with liver inflammation in chronic hepatitis B. Inflamm Res. 2011; 60
: 47─53.

18. Peng G, Luo B, Li J, Zhao D, Wu W, Chen F, et al. Hepatitis B e-antigen persistency is

associated with the properties of HBV-specific CD8 T cells in CHB patients. J Clin
Immunol. 2011;31: 195─204.

19. Boni C, Fisicaro P, Valdatta C, Amadei B, Di Vincenzo P, Giuberti T. Characterization

of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. J
Virol. 2007;81: 4215─25.

20. Bengsch B, Martin B, Thimme R. Restoration of HBV-specific CD8+ T cell function

by PD-1 blockade in inactive carrier patients is linked to T cell differentiation. J
Hepatol. 2014; 61: 1212─9.

21. Evans A, Riva A, Cooksley H, Phillips S, Puranik S, Nathwani A, et al. Programmed

death 1 expression during antiviral treatment of chronic hepatitis B: Impact of hepatitis
B e-antigen seroconversion. HEPATOLOGY. 2010; 48(3): 759─69.

22. Fisicaro P, Valdatta C, Massari M, Loggi E, Biasini E, Sacchelli L. Antiviral

intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway
in chronic hepatitis B. Gastroenterology. 2010;138: 682─93.

23. Tzeng HT, Tsai HF, Liao HJ, Lin YJ, Chen L, Chen PJ, et al. PD-1 blockage reverses
immune dysfunction and hepatitis B viral persistence in a mouse animal model. PLoS
ONE. 2012 June; 7(6): 1─9.
24. Isogawa M, Chung J, Murata Y, Kakimi K, Chisari FV. CD40 activation rescues
antiviral CD8+ T cells from PD-1-mediated exhaustion. PLoS Pathog. 2013; 9(7):
1─16.

25. Liu J, Zhang E, Ma Z, Wu W, Kosinska A. Enhancing virus-specific immunity in vivo

by combining therapeutic vaccination and PD-L1 blockade in chronic hepadnaviral
infection. PLoS Pathog. 2014; 10(1): 1─14.

26. Cheng HY, Kang PJ, Chuang YH, Wang YH. Circulating programmed death-1 as a
marker for sustained high hepatitis B viral load and risk of hepatocellular carcinoma.
Plos One. 2014 November; 9(11): 1─15.

27. Liaw YF, Chu CM. Hepatitis B virus infection.. 2009;373(9663):582-92. Lancet. 2009;
373(9663): 583─92.

28. Chan HL, Alex T, Peignoux MM, Piratvisuth T, Comberg M, Brunetto MR. Hepatitis B
surface antigen quantification:Why and how to use it in 2011-a core group report. J of
Hepatology. 2011; 30: 1─11.

29. Hadiziyannis E. Quantification of HBsAg in serum:characteristic of the assay. OA

Hepatology. 2013: 1─6.

30. Lee JM, Ahn SH. Quantification of HBsAg:Basic virology for clinical practice. World J
of Gastroenterol. 2011; 17: 283─9.

31. Tseng TC, Kao JH. Clinical utility of quantitative HBsAg in natural history and
nucleos(t)ide analogue treatment of chronic Hepatitis B: new trick of old dog. J
Gastroenterol. 2013; 48: 13─21.

32. Te HS, Jensen DM. Epidemiology of hepatitis B and C viruses : a global overview. Clin
Liver Dis. 2010; 14(1): 1─21.

33. Shire NJ. Cure strategies for hepatitis B virus: The promise of immunotherapy. The
American College of Clinical Pharmacology. 2017; 6(2): 186─94.

34. Jules L, Dienstag. Hepatitis B virus infection. N Engl J Med. 2008; 359: 1486─1500.

35. Lavanchy D. Worldwide epidemiology of HBV infection, disease burden, and vaccine
prevention. JClin Virol. 2005; 34(1): 1─3.

36. WGO Practice Guideline Hepatitis B. In World Gastroenterology Organisation; 2008:

1─29.
37. Slederdissen CH, Conberg M. The role of HBsAg level in the current management of
chronic HBV infection. Annals of Gastroenterology. 2014; 27: 1─8.

38. Martanne G, Zekry A. Natural hystory of chronic hepatitis B virus infection.

Gastroenterology and Hepatology Department, St George hospital, Kongarah. 2009:
40─5.

39. You CR, Lee SW, Jang JW, Yoon SK. Update on hepatitis B virus infection. World J
Gastroenterol. 2014 Oktober; 20(37): 13293─305.

40. Wu J, Meng Z, Jiang M, Pei R , Trippler M , Broering R. Hepatitis B virus suppresses

toll-like receptor-mediated innate immune responses in murine parenchymal and
nonparenchymal liver cells. Hepatology. 2009; 49: 1132─40.

41. Zhang JY, Zou ZS, Huang A, Zhang Z, Fu JL, Xu XS. Hyper-activated pro-
inflammatory CD16 monocytes correlate with the severity of liver injury and fibrosis in
patients with chronic hepatitis B. PLoS One. 2011; 6: e17484:24─33.

42. Chen MT, Billaud JN, Sallberg M, Guidotti LG, Chisari FV, Jones J. A function of the
hepatitis B virus precore protein is to regulate the immune response to the core antigen.
Proc Natl Acad Sci USA. 2004; 101: 14913─8.

43. Hakim MS, Spaan M, Harry L, Jansen A, Boonstra A. Inhibitory receptor molecules in
chronic hepatitis B and C infections: novel targets for immunotherapy? Rev. Med.
Virol. 2014; 24: 125─38.

44. Bertoletti A, Ferrari C. Innate and adaptive immune responses in chronic hepatitis B
virus infections: towards restoration of immune control of viral infection.. Gut. 2012;
61: 1754─64.

45. Michel ML, Deng Q, Bourgine MM. Therapeutic vaccines and immune-based therapies
for the treatment of chronic hepatitis B: perspectives and challenges. J Hepatol. 2011;
54: 1286─96.

46. Petrovas C, Casazza JP, Brenchley JM, Price DA, Gostick E, Adam WC. PD-1 is a
regulator of virus-specific CD8+ T cell survival in HIV infection. J Exp Med. 2006;
203: 2281─92.

47. Chisari FV. Rous-Whipple Award Lecture. Viruses, immunity, and cancer: lessons from
hepatitis B. Am J Pathol. 2000; 156: 1117─32.

48. Schmidt J, Blum HE, Thimme R. Julia Schmidt, Hubert E Blum and Robert Thimme.
T-cell responses in hepatitis B and C virus infection: similarities and differences.
 Emerging Microbes and Infections. 2013; e15: 1─8.

49. Ye B, Liu X, Li X, Kong H, Tian L , Chen Y. T-cell exhaustion in chronic hepatitis B

infection: current knowledge and clinical significance. Cell Death and Disease. 2015;
6(42): 1─10.

50. Balmasova IP, Yushchuck ND, Mynbaev OA, Alla NR, Malova ES, Shi Z.
Immunopathogenesis of chronic hepatitis B. World J Gastroenterol. 2014 October;
20(39):14516─71

51. Ferrari C. HBV and the immune response. Liver Int. 2015; 35(1): 121─8.

52. Luneman S, Malone DF, Hengst J. Compromised function of natural killer cells in acute
and chronic viral hepatitis. J Infect Dis. 2014; 209: 1362─73.

53. Boni C, Laccabue D, Lampertico P. Restored function of HBV-specific T cells after

long term effective therapy with nucleos(t)ide nalogues. Gastroenterology. 2012; 143:
963─73.

54. Grimm D, Heeg M, Thimme R. Hepatitis B virus: from immunobiology to

immunotherapy. Clinical Science. 2013; 124: 77─85.

55. Human IFN-γ High Sensitivity ELLISA BMS228HS: eBioscience; 2017:1─39.

56. Schroder K, Hertzog P, Ravasi T, Hume D. Interferon-gamma: an overview of signals,

mechanism and functions. J. Leukoc. Biol. 2004; 75(2): 163─89.

57. Bonino F, Piratvisuth T, Brunetto MR, Liaw Y. Review Diagnostic markers of chronic
hepatitis B infection and disease. 2010; 44: 35─44.

58. Tong S, Kim KH, Chante C, Wands J, Li J. Hepatitis B virus e antigen variants. Int. J.
Med. Sci. 2005; 2(1): 2─7.

59. Rajbhandari R, Chung RT. Treatment of hepatitis B : a concise review. The American
College of Gastroenterology. 2016 July; 7(10): 1─10.

60. Ma L, Cai YJ, Yu L, Feng JY, Wang J, Li C. Treatment with telbivudine positively
regulates antiviral immune. Antimicrobial Agents and Chemotherapy. 2013;
57(3):1304─11

61. Gish R, Jia JD, Locarnini S, Zoulim F. Selection of chronic hepatitis B therapy with
high barrier to resistance. Lancet Infect Dis. 2012; 12: 341─53.

62. Bertoletti A, Rivino L. Hepatitis B: future curative. Curr Opin Infect Dis. 2014; 27:
 528─34.

63. Loggi E, Vitale G, Conti F, Bernardi M, Andreone P. Chronic hepatitis B: Are we close
to a cure? Digestive and Liver Disease. 2015; 47: 836─41.

64. Michel ML, Deng Q, Bourgine MM. Therapeutic vaccines and immune-based therapies
for the treatment of chronic hepatitis B: perspectives and challenges. J Hepatol. 2011;
54: 1286─96.

65. Koh S, Shimasaki N, Suwanarusk R. A practical approach to immunotherapy of

hepatocellular carcinoma using T cells redirected against hepatitis B virus. Mol Ther
Nucleic Acids. 2013; 2: e114:1─9.

66. Forbi JC, Iperepolu OH, Zungwe T, Agwale SM. Prevalence of hepatitis B e antigen in
chronic HBV carries in north-central Nigeria. J HEALTH POPUL NUTR. 2012 Dec 30;
4: 377─82.

67. Khan F, Shams S, Qureshi ID, Israr M, Khan H, Sarwar MT. Hepatitis B virus infection
among different sex and age groups in Pakistani Punjab. Virology Journal. 2011;
8(225): 1─5.

68. Chen P, Yu C, Wu W, Wang J, Ruan B, Ren J, et al. Serological profile among HBsAg-
positive infection in southeast China: a community-based study. Hepat Mon. 2013;
13(1): 1─6.

69. Su WC, Hsieh TC, Hsieh TY, Tseng KC, Peng CY, Lin CL, et al. Younger age and
female sex predict a better therapeutic response in HBeAg-positive chronic hepatitis B
patients to entecavir therapy. Advances in Digestive Medicine. 2014; 1: 112─7.

70. Utama A, Siburian MD, Purwantomo S, Intan MD, Kurniasih TS, Gani RA, et al.
Association of core promoter mutations of hepatitis B virus and viral load is different in
HBeAg(+) and HBeAg(-) patients. World J Gastroenterol. 2011; 17(6): 708─16.

71. Pribadi J, Gani RA, Syam AF, Lesmana CR, Bela B, Setiati s, et al. Pola mutasi
resistensi terhadap analog nukleos(t)ida virus hepatitis B pada pengidap kronis yang
belum mendapatkan terapi. In Tesis; Jakarta:Universitas Indonesia; 2013:1─65.

72. Syam S, Zubir N, Arnelis , Najirman. Pola mutasi resistensi virus hepatitis B terhadap
analog nukleos(t)ida pada pasien hepatitis B kronis naive etnik minangkabau. In Tesis;
Padang: Universitas Andalas; 2014: 1─75.

73. Trisnaningtyas RW, Sari CP, Setyaningrum N. Evaluasi terapi pada pasien hepatitis B
di RSUP Dr. Sardjito Yogyakarta. Jurnal Ilmiah Farmasi. 2017 Jan; 1: 29─34.
74. Li N, Zhou Z, Li F, Sang J, Han Q, Lv Y, et al. Circulating soluble programmed death-1
levels may differentiate immune-tolerant phase from other phase and HCC from other
clinical disease in CHB virus infection. Oncotarget. 2017; 8(28): 46020─33.

75. Bi C, Huang D, Jiang J, Wang H, Bian C, Tian Z. Changes of serum sPD-1 levels in
HBeAg-positive CHB patients with entecavir treatment and correlation with curative
effect. Turkish Journal of Medical Sciences. 2018; 48: 286─92.

76. Zhang WJ, Peng CH, Zheng SS. Programmed death 1 and programmed death ligand 1
expressions in patients with chronic hepatitis B. Hepatobiliary Pancreat Dis Int. 2013;
12(4): 394─9.

77. Zhang Z, Zhang JY, Wang LF, Wang FS. Immunopathogenesis and prognostic immune
markers ofChronic hepatitis B virus infection. Journal of Gastroenterology and
Hepatology. 2012; 27: 223─30.

78. Ying XD, Liang LB, Juan CF, Hong D, Tian CY, Hong ZX, et al. Programmed death-1
( PD-1) and PD-L 1 expression during antiviral treatment of chronic hepatitis B. Chin J
Hepatol. 2010; 18(9):646─50.

79. Trehanpati N, Kotillil S, Hissar SS, Shrivastava S, Khanam A, Sukriti S, et al.

Circuating Circulating Tregs correlate with viral load reduction in chronic HBV-treated
patients with tenofovir disoproxil fumarate. J Clin Immunol. 2011 Februari; 31:
509─20.

80. Vanwolleghem T, Hou J, Oord GV, Andeweg AC, Osterhaus AD, Pas SD. Re-
evaluation of Hepatitis B virus clinical phases by systems biology identifies
unapppreciated roles for the innate immune response and B cells. Hepatology aasld.
2015 July; 62(1): 87─100.

81. Rizvi M, Azam M, Ajmal MR, Malik A, Shukla I, Afroz N. Role of interferon-gamma
and interleukin-12 the immunophatogenesis of hepatitis B virus infection. EJOHG.
2012 January-June; 2(1): 5─9.

82. Schreiber GH, Scheiber RD. Interferon-gamma. In: Thomson AW, Lotze MT, editors.
The Cytokine Handbook. 1. Fourth ed. California-USA: Academic Press-Elsevier;
2003: 567─602.

83. Wahyuniati N. Peran interferon-gamma pada infeksi. JKS. 2017 Agustus; 17(2):
126─32.